News NetraMark Holdings Inc. Canadian Securities Exchange

Stocks

AIAI

CA64119M1059

Software

End-of-day quote Canadian Securities Exchange Other stock markets 20/02/2026			5-day change	1st Jan Change
1.070 ^CAD	-.--%		-3.77%	-7.27%

29/06	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
29/06	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI

All News

Mentions Relevance

29/06	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
29/06	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI
29/06	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	AQ
09/06	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
25/05	Upcoming Meeting Dates - May 25, 2026	NE
20/05	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
15/05	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
15/05	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
08/05	NetraMark Announces Change To Board Of Directors	AQ
08/05	NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026	CI
05/05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE
04/05	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI	AQ
04/05	NetraMark Holdings Inc. Announces Executive Changes	CI
30/04	NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026	AQ
22/04	NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	AQ
22/04	NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	CI
20/04	Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development	AQ
20/04	NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics	CI
09/04	Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes	CI
09/04	Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain	AQ
25/03	NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset	MT
25/03	Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration	CI
25/03	NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset	MT
25/03	NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset	AQ
19/03	NetraMark Holdings Inc Unveils Ai-Discovered Treatment-Responsive Subgroups In A4 Alzheimer?s Trial	CI